This article overviews the pharmacological properties and clinical efficacy and tolerability of ADVATE in the context of personalised prophylaxis for haemophilia A facilitated by myPKFiT, which is a software tool for clinicians that predicts individual pharmacokinetic profiles for patients and calculates an appropriate ADVATE prophylaxis dosing regimen.
Commentary and recommendations from Dr Jane Mason, a paediatric and general Haematologist. She holds a dual appointment with Queensland Haemophilia Centre and QML Pathology.
Please login below to download this issue (PDF)